Pre-Seed Biotech Fundraising With No Clinical Data: How to Raise Before You Have Proof

Every pre-seed biotech founder runs into the same wall. Investors want to see that the science works. But generating the data that proves the science works costs money — money you’re trying to raise. You need capital to produce results, and you’re being told you need results to attract capital. It is the defining catch-22 of the earliest stage, and it stops a lot of good founders before they start.

Here is the reframe that gets you past it: at pre-seed, you are not selling data. You cannot, because you don’t have any yet — and the investors who fund this stage know that. The traditional biotech path assumed a founder would develop preliminary results and only then take that data to venture capitalists, but as Nature Biotechnology has noted, that playbook increasingly leaves out the many founders tackling ambitious, capital-intensive science who don’t yet fit those criteria.

The founders who raise pre-seed successfully today are the ones who understand what actually gets funded before there’s proof: a credible team, defensible IP, a compelling scientific rationale, a real market, and a precise plan for the first data point — pitched to the specific investors whose entire thesis is backing science before it’s de-risked.

That targeting discipline matters more in this market than it did two years ago. Early-stage biotech financings are on track for their worst year since before the pandemic, with first-time rounds heading toward their lowest count this decade as investors continue to concentrate capital in later-stage companies. The capital is still there — but it is more selective, which makes precision in how you position and who you approach the difference between a raise and a dead end.

This guide: Pre-Seed Biotech Fundraising With No Clinical Data is the tactical version of that argument: what substitutes for data, who actually writes checks pre-proof, how to build a milestone narrative that makes a pre-data raise fundable, the mistakes that quietly kill these rounds, and a practical 12-month roadmap to get there.

The pre-seed reality: what you’re actually selling when you have no data

Pre-seed investors bet on the team and the science, not results

The first thing to internalize is that pre-seed and seed are fundamentally different games. Seed-stage investors expect demonstrable progress toward commercialization and want evidence the technology works outside a controlled lab. Pre-seed investors, by contrast, are betting on the founding team and the scientific promise before that proof exists. The entire company-creation model practiced by firms like ARCH Venture Partners, Third Rock Ventures, and Flagship Pioneering is built on funding science before it has been de-risked, not after.

This is possible because the people making these decisions can evaluate the science directly. Many early-stage biotech funds are led by PhDs, MDs, and former operators who assess the underlying biology themselves rather than waiting for a dataset to do the convincing. When you pitch a pre-seed biotech investor, you are often pitching someone with the scientific training to be persuaded by mechanism, rationale, and experimental design — not just results.

The honest truth: some investors won’t engage pre-data, and that’s fine

Here is the part most guides skip. A large share of biotech capital genuinely will not look at you before you have data — and in a market where investors are visibly favoring later-stage companies, that share is not shrinking. Pitching those funds with no data isn’t brave; it’s a waste of your runway and theirs.

The skill at pre-seed is not convincing data-stage investors to lower their bar. It’s identifying the specific subset of funders whose mandate is to back you now, and concentrating your energy there. Targeting is half the battle, and getting it wrong is the most common way pre-data founders burn months.

What “de-risked enough” means before you have data

Even without results, investors are looking for evidence that you’ve reduced some of the risk. De-risking pre-data is about removing doubt on every dimension you can control: a team that can clearly execute, IP that creates a real barrier, a mechanism that holds up to scientific scrutiny, a market that obviously exists, and a plan whose first milestone is concrete and achievable with the money you’re asking for. You can’t de-risk the biology yet — that’s what the round is for. You can de-risk everything around it.

The five things that substitute for clinical data at pre-seed

When there’s no data in the room, five things carry the weight. Treat these as the spine of your raise.

1. The founding team — your single biggest asset pre-data

At pre-seed, the team is the investment. Investors expect a strong, well-balanced founding team that can execute — and PhDs, MDs, former biotech executives, and recognized domain experts carry real weight, because at this stage your credibility is the proxy for your eventual data. Make the team the front of your story: who you are, why you specifically are equipped to solve this problem, what you’ve published or built before, and which gaps you’ve filled with advisors or co-founders. A balanced team that pairs deep science with some commercial or operational capability signals you can actually run a company, not just a lab.

2. Intellectual property and defensibility

In the absence of data, IP becomes the most concrete asset you can point to. In the preclinical stage, biotech companies are valued largely on the strength of their intellectual property, and secured patents or exclusive licenses measurably increase investor confidence. Your IP needs to create a real barrier to entry — patents, licenses, or proprietary technology that competitors can’t easily route around. If your science came out of a university, your licensing position is part of the story; investors will want to know you actually control the rights to what you’re building on.

3. A compelling scientific rationale and mechanism

You may not have results, but you must have a rigorous, defensible explanation of why this will work. Expect investors to probe the mechanism hard: why does this approach work, what is the biological basis, and why will the data — when it exists — confirm it? This is where a scientist-founder has the advantage. A clear, well-reasoned mechanistic argument, grounded in the existing literature and your own prior work, can carry enormous weight with a scientifically trained investor. The goal is to make the biology so coherent that the data feels like a formality waiting to happen.

4. Market size and unmet clinical need

Science without a market doesn’t get funded, no matter how elegant. Investors will ask who pays for this and whether there’s a clear reimbursement path. The most compelling framing ties your science directly to a large, unmet clinical need and to real patient consequences — it makes the opportunity tangible and shows you understand that you’re building a company, not running an experiment. Be specific about the patient population, the current standard of care and its failures, and why your approach is meaningfully better.

5. A credible, milestone-based de-risking plan

The final pillar is the one that turns the other four into an investable round: a clear plan for what the money buys. The strongest founders break development into manageable, de-risked steps — preclinical results, IND-enabling work, early clinical signals — rather than presenting an all-or-nothing roadmap. Your pre-seed plan should make crystal clear which specific, value-creating milestone this capital will deliver, because that milestone is what makes your next round the de-risked one.

Who actually funds pre-data biotech

Knowing what to sell is half of it. The other half is knowing who’s buying at this stage. There are four distinct sources, and most pre-data founders should pursue several in parallel.

Specialist accelerators

For genuinely pre-data biotech, accelerators are often the most realistic first institutional money — they’re built for exactly this moment. SOSV’s IndieBio writes pre-seed checks of up to roughly $550,000, is almost always the first VC investor in a company, targets around 10% ownership by the seed round, and runs an intensive four-to-five-month program with wet-lab access — reserving the majority of its fund for follow-on rounds rather than a single first check.

Programs like Y Combinator’s bio track, Johnson & Johnson’s JLABS (which takes no equity), and the Illumina Accelerator offer their own mixes of capital, lab space, and mentorship. The value here isn’t only the check — it’s the validation, the wet-lab infrastructure to generate your first data, and the warm path into the next round.

Pre-seed life-science funds and domain-expert angels

A growing set of specialist funds write first institutional checks at the idea stage. Some write first checks of roughly $500K–$5M at the earliest stages for science-first founders applying compute to chemistry and biology, and the company-creation firms routinely back founders from the ground up. The practical move, as Atlas Venture’s Bruce Booth advises, is to build a list of every biotech VC you can name and filter it by focus area, stage, business model, and geography to find the firms whose thesis actually matches a pre-data company like yours.

Founders building AI- or computation-led platforms should be especially deliberate about how they frame that edge for investors, since the story is easy to overstate and hard to make legible. Domain-expert angels — former operators, physicians, and scientists in your field — punch far above their check size at this stage, because their participation is itself a credibility signal.

The non-dilutive bridge — SBIR/STTR, foundations, and grants

This is the lane that changes the math for pre-data biotech, and too few founders use it well. Through the SBIR and STTR programs — known collectively as America’s Seed Fund, coordinated by the Small Business Administration across 11 federal agencies — the federal government awards billions of dollars a year in non-dilutive funding to move technology toward commercialization. “Non-dilutive” is the key word: you take no equity hit.

One critical update every founder should know: the programs’ authorization lapsed on September 30, 2025, pausing new awards, before Congress reauthorized SBIR and STTR through 2031 in the Small Business Innovation and Economic Security Act, which President Trump signed into law in April 2026 alongside structural reforms, including a new “Strategic Breakthrough” award category and enhanced national-security screening of applicants. With the programs restarting, agencies are updating their FY2026 solicitation schedules — so verify current deadlines directly before you plan around them.

Within that system, the NIH is the single largest source of non-dilutive capital for health-tech startups, directing well over $1 billion a year to small businesses, with Phase I awards of roughly $300,000 for six-to-twelve months of feasibility work, Phase II awards up to about $2 million over two years, and standard application deadlines on January 5, April 5, and September 5.

Crucially for the earliest-stage founder, NIH Phase I generally does not require preliminary data — meaning you can apply at the hypothesis stage, before the preclinical package a seed round would demand. Use these awards to generate your first data without giving up ownership, so the equity round you raise next is the de-risked one investors compete for. Disease-specific foundations and patient-advocacy organizations — the Cystic Fibrosis Foundation, JDRF, the Michael J. Fox Foundation, and cancer-focused programs among them — operate similarly and are worth mapping alongside the federal programs.

Friends, family, and founder capital — used wisely

At the very earliest point, founders frequently contribute personal capital and raise from friends, family, and angels alongside applying to accelerators and grant programs. This money is fast and relationship-based, but treat it with discipline: use clean instruments (a standard SAFE), set clear expectations about the risk, and deploy it specifically to reach the first milestone that unlocks accelerator, grant, or institutional money. The goal of every dollar at this stage is to buy the proof point that makes the next dollar cheaper.

Construct the milestone narrative: turn “no data” into “this capital buys this proof”

The single most important pitch move for a pre-data founder is reframing the raise around a milestone. You are not asking investors to fund a company indefinitely on faith. You are asking them to fund one specific, value-creating experiment.

Frame the raise around a single value-inflection point. Identify the one result that most de-risks your company — the proof-of-concept assay, the animal-model readout, the lead-candidate validation — and build your entire ask around delivering it. “This round takes us to [specific milestone], which is the inflection point that unlocks our seed round” is a far stronger pitch than “this round funds 18 months of research.” Accelerators model this explicitly, agreeing on value-inflection milestones up front and tracking against them. Investors fund milestones, not timelines.

Break the path into de-risked steps. Show the whole staircase, not just the next step. Lay out the sequence from where you are to a fundable seed round, with each step visibly reducing risk. It signals that you understand how biotech value is actually built — and many founders now pair this with an incremental approach, raising smaller amounts across milestone-tied rounds to preserve control and reduce dilution.

Be realistic about timelines. Nothing destroys pre-data credibility faster than overpromising. Investors know drug and device development takes time, and an aggressive, implausible path makes a founder look either naive or dishonest — both fatal at a stage where the investor is betting almost entirely on your judgment. Build in realistic buffers, acknowledge the hard parts, and let your credibility come from rigor rather than optimism.

Build the rest of the pre-seed package

With your substance in place, the materials need to match.

The scientific-narrative pitch deck

Biotech is documentation-heavy, and your deck needs to carry a clear scientific narrative — not a wall of jargon, but a logical arc from problem to mechanism to milestone to market. Lead with the team and the unmet need, make the rationale legible to a smart investor who isn’t a specialist in your exact niche, name your scientific advisors and why each was recruited, and end on the milestone the round delivers. Clarity is a credibility signal in itself.

A clean, organized data room — even with no data

You may have no results, but you still have material: IP filings and licensing agreements, founder and advisor CVs, your scientific rationale and references, your development plan and budget, and any letters of support or collaboration. A structured, well-organized data room at pre-seed signals operational discipline — exactly the reassurance an investor needs when they can’t yet evaluate your data.

Capital efficiency and use of funds

Show investors precisely how their money converts into progress, and tie every major line item to the milestone it advances. Capital efficiency — doing more with less, using affordable CROs and shared lab infrastructure — is especially attractive in a cautious market that is rewarding discipline.

Strengthen what you can’t put in a data room: founder credibility

When there’s no dataset to do the talking, the founder’s visible credibility carries disproportionate weight. An investor doing diligence on a pre-data company is, in large part, doing diligence on you — and what they find when they look you up shapes their confidence before the first meeting.

A founder who has built a visible, credible presence — sharing genuine perspective on their field — gives investors evidence of expertise and judgment that no early-stage data room can. Engaging thoughtfully with the biotech investor community on platforms like LinkedIn puts your work on their radar and warms the path before you ever ask for a meeting. At pre-seed, visibility isn’t vanity — it’s a substitute for the proof you don’t yet have.

For the full system behind this, see How to Build Biotech Founder Visibility Before a Fundraise and Searchable Authority for Healthcare Founders.

Pre-data rounds are also won on relationships as much as substance. The investors most likely to back you before there’s proof are the ones who already know and trust you. Start those conversations months before you need the money, treat an early “no, not yet” as the beginning of a relationship rather than a rejection, and keep the investors you want updated as you hit your milestones.

A practical 12-month roadmap for raising pre-seed without data

The infrastructure above doesn’t assemble itself in the weeks before a raise. Here is how to build it across a year so that formal outreach happens in the back half, after the credibility signals are in place.

Q1 — Foundation (Months 1–3). Formalize your scientific hypothesis in a two-to-three-page rationale document that anchors every investor conversation and grant application. Engage a biotech patent attorney and file a provisional patent to establish your priority date. Research and begin your first non-dilutive application — NIH SBIR Phase I generally needs no preliminary data, so apply early. Build an initial target list of 30–50 stage- and thesis-fit investors, and stand up a simple CRM to track every relationship.

For the targeting and CRM framework, see How to Build an Investor Pipeline for Biotech and Medtech Founders.

Q2 — Credibility (Months 4–6). Generate one clean, well-designed in vitro result that confirms a foundational piece of your hypothesis — not a full preclinical package, just the biological anchor that makes every later conversation more credible. Recruit your first two scientific advisory board members with a specific, defined ask. Launch or sharpen your founder visibility — start publishing substantive perspective on your field — so you’re findable and credible when an investor searches your name. Map every warm-introduction path to your top 10–15 targets before any cold outreach.

Q3 — First conversations (Months 7–9). Begin value-first, research-driven outreach to your highest-priority investors, framed as peer scientific dialogue rather than a pitch. Attend one well-chosen early-stage biotech event with specific people you want to meet. Submit your SBIR application if you haven’t — even a pending submission is a referenceable credibility signal. Send your first quarterly investor update to advisors, angels, and warm contacts.

Q4 — Execute the raise (Months 10–12). Finalize your deck and one-pager, incorporating every piece of evidence built over nine months. Run parallel outreach to your full target list within a tight two-week window to create competitive dynamics. Manage pipeline momentum actively, updating your CRM after every interaction. Close — and on day one after close, begin defining the seed-stage milestones your pre-seed capital will generate.

For the full outreach mechanics, see Capital Raise Marketing for Biotech, Medtech, and Diagnostics.

Common mistakes founders make raising pre-seed without data

Pitching data-stage investors too early. Spending your runway on funds that structurally require clinical data isn’t persistence — it’s mis-targeting. Concentrate on accelerators, pre-seed specialists, domain angels, and non-dilutive sources whose mandate fits your stage.

Overpromising and vague milestones. A plan built on implausible timelines or fuzzy, non-specific milestones undermines the one thing you’re really selling at pre-seed — your judgment. Be concrete about the single proof point this round delivers, and realistic about how long it takes.

No IP strategy. A hypothesis anyone can pursue is not defensible. A provisional patent is inexpensive and fast to prepare with an attorney; there is no good reason to approach investors without one.

No non-dilutive strategy. Founders who haven’t explored SBIR, NIH, or foundation grants before approaching venture investors leave both capital and credibility on the table. A federal award keeps your equity intact and signals that your science survived independent peer review.

Treating pre-seed as just a smaller seed round. Pre-seed and seed are different propositions with different bars. Pitch a pre-seed round on team, IP, rationale, market, and milestone — not on diluted, premature claims of traction you can’t back up.

The bottom line

Raising pre-seed biotech capital with no clinical data isn’t about pretending you have proof you don’t. It’s about understanding that proof is not what this stage funds. The investors who write checks before the science is de-risked are betting on a credible team, defensible IP, a rigorous scientific rationale, a real market, and a precise plan to generate the first meaningful data — and they exist specifically to fund that moment, through accelerators, specialist pre-seed funds, domain angels, and the non-dilutive lane that lets you produce data without surrendering equity.

In a market concentrating capital in later-stage companies, your preparation matters more, not less. Get the targeting right, build your raise around the five pillars that substitute for data, frame the round as the capital that buys one specific value-inflection milestone, and make your own credibility visible enough to stand in for the dataset you don’t yet have. That is how you break the catch-22 — not by waiting for proof you can’t afford to generate, but by raising the round that lets you generate it.

---

Book a Strategy Call to build and pressure-test your pre-seed raise before you start pitching — or Explore My Services to see how founder positioning, investor targeting, and outreach come together for founders raising before they have data.

---

Frequently Asked Questions

---